Liala Moschetti

Dr. Liala Moschetti

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 November 2020 in Rheumatology
Verified
Journal Article
Closed access
MFMarco Fornaro
Marco Fornaro
FRANCESCO GIROLAMOFRANCESCO GIROLAMO
FRANCESCO GIROLAMO
LCLorenzo Cavagna
Lorenzo Cavagna
FFFranco Franceschini
Franco Franceschini
MGMargherita Giannini
Margherita Giannini
Florenzo IannoneFlorenzo Iannone
Florenzo Iannone
Objective: The aim of our study was to investigate clinical and histopathological findings in adult DM patients positive for anti-Mi2 (anti-Mi2+) antibodies compared with DM patients negative for anti-Mi2 (anti-Mi2–). Methods: Clinical data of adult DM patients, who fulfilled EULAR/ACR 2017 classification criteria, were gathered from electronic medical records of three tertiary Rheumatology Units. Histopathological study was carried out on 12 anti-Mi2+ and 14 anti-Mi2– muscle biopsies performed for diagnostic purpose. Nine biopsies from immune mediated necrotizing myopathy (IMNM) patients were used as control group. Results: Twenty-two anti-Mi2+ DM [90.9% female, mean age 56.5 (15.7) years] were compared with 69 anti-Mi2– DM patients [71% female, mean age 52.4 (17) years]. Anti-Mi2+ patients presented higher levels of serum muscle enzymes than anti-Mi2– patients [median (IQR) creatine-kinase fold increment: 16 (7–37)vs 3.5 (1–9.9), P <0.001] before treatment initiation. Moreover, a trend towards less pulmonary involvement was detected in anti-Mi2+ DM (9.1% vs 30.4%, P =0.05), without any case of rapidly progressive interstitial lung disease. At muscle histology, anti-Mi2+ patients showed more necrotic/degenerative fibres than anti-Mi2– patients [mean 5.3% (5) vs 0.8% (1), P 0.05]. In addition, the endomysial macrophage score was similar between anti-Mi2+ and IMNM patients [mean 1.2 (0.9) vs 1.3 (0.5), P >0.05], whereas lower macrophage infiltration was found in anti-Mi2– DM [mean 0.4 (0.5), <0.01]. Conclusions: Anti-Mi2+ patients represent a specific DM subset with high muscle damage. Histological hallmarks were a higher prevalence of myofiber necrosis, endomysial involvement and macrophage infiltrates at muscle biopsy.

18 May 2022 in Clinical and Experimental Rheumatology
Verified
Journal Article
Closed access
LMLiala Moschetti
Liala Moschetti
LPLuisa Dal Pozzolo
Luisa Dal Pozzolo
VGVeronique Le Guern
Veronique Le Guern
NMNathalie Morel
Nathalie Morel
CYCecile M. Yelnik
Cecile M. Yelnik
ATAngela Tincani
Angela Tincani
Full Papers; Authors: L. Moschetti, L. Dal Pozzolo, V. Le Guern, N. Morel, C.M. Yelnik, M. Lambert, E. Hachulla, Y. Benhamou, C. Nalli, M. Fredi, F. Franceschini, L. Andreoli, N. Costeadot-Chalumeau, A. Tincani

1 July 2022 in Current Pharmaceutical Design
Verified
Journal Article
Closed access
PDF file
CFClodoveo Ferri
Clodoveo Ferri
VRVincenzo Raimondo
Vincenzo Raimondo
LGLaura Gragnani
Laura Gragnani
Dilia GiuggioliDilia Giuggioli
Dilia Giuggioli
LDLorenzo Dagna
Lorenzo Dagna
Alessandro AntonelliAlessandro Antonelli
Alessandro Antonelli
Objective: Autoimmune systemic diseases (ASD) represent a predisposing condition to COVID-19. Our prospective, observational multicenter telephone survey study aimed to investigate the prevalence, prognostic factors, and outcomes of COVID-19 in Italian ASD patients. Method: The study included 3,918 ASD pts (815 M, 3103 F; mean age 59±12SD years) consecutively recruited between March 2020 and May 2021 at the 36 referral centers of COVID-19 and ASD Italian Study Group. The possible development of COVID-19 was recorded by means of a telephone survey using a standardized symptom assessment questionnaire. Results: ASD patients showed a significantly higher prevalence of COVID-19 (8.37% vs. 6.49%; p< 0.0001) but a death rate statistically comparable to the Italian general population (3.65% vs. 2.95%). Among the 328 ASD patients developing COVID-19, 17% needed hospitalization, while mild-moderate manifestations were observed in 83% of cases. Moreover, 12/57 hospitalized patients died due to severe interstitial pneumonia and/or cardiovascular events; systemic sclerosis (SSc) patients showed a significantly higher COVID-19-related death rate compared to the general population (6.29% vs. 2.95%; p=0.018). Major adverse prognostic factors to develop COVID-19 were: older age, male gender, SSc, pre-existing ASD-related interstitial lung involvement, and long-term steroid treatment. Of note, patients treated with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) showed a significantly lower prevalence of COVID-19 compared to those without (3.58% vs. 46.99%; p=0.000), as well as the SSc patients treated with low dose aspirin (with 5.57% vs. without 27.84%; p=0.000). Conclusion: During the first three pandemic waves, ASD patients showed a death rate comparable to the general population despite the significantly higher prevalence of COVID-19. A significantly increased COVID-19- related mortality was recorded in only SSc patients’ subgroup, possibly favored by preexisting lung fibrosis. Moreover, ongoing long-term treatment with csDMARDs in ASD might usefully contribute to the generally positive outcomes of this frail patients’ population.

23 July 2022 in Clinical and Experimental Rheumatology
Verified
Journal Article
Closed access
LMLiala Moschetti
Liala Moschetti
MLMaria Grazia Lazzaroni
Maria Grazia Lazzaroni
ICIlaria Cavazzana
Ilaria Cavazzana
FFFranco Franceschini
Franco Franceschini
PAPaolo Airò
Paolo Airò
Full Papers; Authors: L. Moschetti, M.G. Lazzaroni, I. Cavazzana, F. Franceschini, P. Airò

8 March 2021 in Expert Opinion on Drug Safety
Verified
Journal Article
Closed access
ATAnna Viola Taulaigo
Anna Viola Taulaigo
LMLiala Moschetti
Liala Moschetti
SGSara Ganhão
Sara Ganhão
MGMaria-Chiara Gerardi
Maria-Chiara Gerardi
FFFranco Franceschini
Franco Franceschini
LALaura ANDREOLI
Laura ANDREOLI
Systemic lupus erythematosus (SLE) mainly affects young females during childbearing age, therefore reproductive issues are of major interest. Pregnancy planning is crucial to adjust the treatment t...

24 February 2025 in Journal of Scleroderma and Related Disorders
Verified
Journal Article
Closed access
MLMaria Grazia Lazzaroni
Maria Grazia Lazzaroni
LMLiala Moschetti
Liala Moschetti
EPEleonora Pedretti
Eleonora Pedretti
LALaura ANDREOLI
Laura ANDREOLI
FRFrancesca Ramazzotto
Francesca Ramazzotto
FFFranco Franceschini
Franco Franceschini
Objective: The impact of disease on women’s health-related quality of life has become increasingly important in patients with rheumatic diseases (RDs). Systemic sclerosis (SSc) mostly affects women with a broad spectrum of clinical presentations and severity, and a variable impact on daily living. The objective of the present study was to specifically address “women’s health” in systemic sclerosis patients through a dedicated questionnaire. Methods: An anonymous self-reported questionnaire (only in Italian) was developed in collaboration with obstetricians and gynecologists and subsequently revised and approved by five patient representatives. The questionnaire was administered to SSc patients during scheduled visits in an outpatient Rheumatology SSc Clinic. Results: Between April 2021 and March 2023, 168 patients accepted to participate; among them, 44.1% had received their SSc diagnosis during reproductive age (<45 years). The questionnaire was composed of 44 questions and included 5 sections encompassing different topics. A high rate of adherence to female cancer screening programs was recorded (86.9% for cervix and 93.6% for breast cancer), while a non-regular gynecological follow-up was observed in 36.4%, mostly in patients with more severe disease phenotype. Only 42.3% accepted to compile the Female Sexual Function Index (FSFI), which indicated a sexual dysfunction (score ⩽ 26.55) in 66.2% of patients. A worse sexual function was shown to be associated with different disease manifestations, including digital ulcers. More than 90% of patients who expressed a desire for pregnancy after diagnosis received medical pre-conception counseling and were satisfied with the information provided. In contrast, discussion about contraception occurred in 37.8% of patients who had been diagnosed during fertile age. Family planning still represents an unmet need, as 43.6% of patients did not achieve their desired family size, mainly due to concerns about their capacity to care for their children. Conclusion: The newly developed questionnaire provides a unique opportunity to comprehensively assess the experience of women with SSc. Disease burden was shown to negatively impact sexual function and adherence to regular gynecological visits. Furthermore, receiving a diagnosis during reproductive age may increase the likelihood of a reduced family size. Clinicians who take care of women with SSc should implement these domains into routine management, thus improving the health literacy of their patients.